Nanocarrier strategies to overcome P-glycoprotein-mediated drug resistance in cancer therapy

• Andreina Quevedo-Enríquez,
• Katty Yi Zhang,
• Denisse Yajaira Enriquez,
• Byron Raul Inapanta,
• Roxana Noemí Peroni and
• Christian Rafael Quijia

Beilstein J. Nanotechnol. 2026, 17, 882–921, doi:10.3762/bjnano.17.64

• . Keywords: cancer chemotherapy; efflux transporters; multidrug resistance (MDR); nanoparticles; siRNA nanocarriers; tumor-targeted therapy; Review 1 Introduction 1.1 Cancer and current challenges in chemotherapy Cancer remains one of the leading causes of mortality worldwide, with millions of new cases

• compromised by multidrug resistance (MDR), a phenomenon in which cancer cells evade the cytotoxic effects of drugs through various mechanisms. Overexpression of efflux transporters, particularly P-glycoprotein (P-gp), is a well-documented contributor to this phenotype, although it is not the sole mechanism

• , drug detoxification, drug sequestration by lysosomes, overexpression of efflux transporters, and enhanced DNA repair, have become obstacles to cancer therapy [14][15][16]. Among these, elevated drug efflux via cell membrane transporters, particularly P-glycoprotein, has been extensively documented as

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• DNA repair ability, the expression of anti-apoptotic proteins, and the drug efflux transporters of the leukemia stem cells are considered the main contributors to the resistance to chemo- and radiotherapy of many types of leukemia. Hence, it is logical to identify this cell population as a prime

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity

• Sebastian Pieper,
• Hannah Onafuye,
• Dennis Mulac,
• Jindrich Cinatl Jr.,
• Mark N. Wass,
• Martin Michaelis and
• Klaus Langer

Beilstein J. Nanotechnol. 2019, 10, 2062–2072, doi:10.3762/bjnano.10.201

• . The expression of efflux transporters such as the ATP-binding cassette (ABC) transporter ABCB1 is an important resistance mechanism in therapy-refractory cancer cells. Drug encapsulation into nanoparticles has been shown to bypass efflux-mediated drug resistance, but there are also conflicting results